Cypress Capital Group Eli Lilly & CO Transaction History

Cypress Capital Group

$879 Million
Q3 2024

A detailed history of Cypress Capital Group transactions in Eli Lilly & CO stock. As of the latest transaction made, Cypress Capital Group holds 54,848 shares of LLY stock, worth $43.2 Million. This represents 5.53% of its overall portfolio holdings.

Number of Shares

54,848

Previous 56,265 2.52%

Holding current value

$43.2 Million

Previous $50.9 Million 4.61%

% of portfolio

5.53%

Previous 6.16%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$772.14 - $960.02 $1.09 Million - $1.36 Million	-1,417 Reduced 2.52%	54,848 $48.6 Million
Q2 2024 Jul 25, 2024	SELL	$724.87 - $909.04 $1.57 Million - $1.97 Million	-2,171 Reduced 3.72%	56,265 $50.9 Million
Q1 2024 May 08, 2024	BUY	$592.2 - $792.28 $310,312 - $415,154	524 Added 0.9%	58,436 $45.5 Million
Q4 2023 Jan 24, 2024	SELL	$525.19 - $619.13 $1.11 Million - $1.31 Million	-2,112 Reduced 3.52%	57,912 $33.8 Million
Q3 2023 Nov 02, 2023	SELL	$434.7 - $599.3 $430,787 - $593,906	-991 Reduced 1.62%	60,024 $32.2 Million
Q2 2023 Jul 26, 2023	SELL	$350.74 - $468.98 $176,422 - $235,896	-503 Reduced 0.82%	61,015 $28.6 Million
Q1 2023 May 04, 2023	SELL	$310.63 - $364.82 $2.69 Million - $3.16 Million	-8,654 Reduced 12.33%	61,518 $21.1 Million
Q4 2022 Feb 14, 2023	SELL	$321.55 - $374.67 $1.01 Million - $1.18 Million	-3,139 Reduced 4.28%	70,172 $25.7 Million
Q3 2022 Nov 04, 2022	SELL	$296.48 - $337.87 $874,912 - $997,054	-2,951 Reduced 3.87%	73,311 $23.7 Million
Q2 2022 Jul 26, 2022	SELL	$278.73 - $327.27 $1.21 Million - $1.42 Million	-4,324 Reduced 5.37%	76,262 $24.7 Million
Q1 2022 May 16, 2022	SELL	$234.69 - $291.66 $53,744 - $66,790	-229 Reduced 0.28%	80,586 $23.1 Million
Q4 2021 Feb 15, 2022	SELL	$224.85 - $279.04 $181,004 - $224,627	-805 Reduced 0.99%	80,815 $22.3 Million
Q3 2021 Oct 12, 2021	SELL	$221.6 - $272.71 $114,124 - $140,445	-515 Reduced 0.63%	81,620 $18.9 Million
Q2 2021 Jul 13, 2021	SELL	$180.55 - $233.54 $87,025 - $112,566	-482 Reduced 0.58%	82,135 $18.9 Million
Q1 2021 Apr 14, 2021	SELL	$164.32 - $212.72 $163,334 - $211,443	-994 Reduced 1.19%	82,617 $15.4 Million
Q4 2020 Jan 12, 2021	BUY	$130.46 - $172.63 $248,917 - $329,378	1,908 Added 2.34%	83,611 $14.1 Million
Q3 2020 Oct 08, 2020	SELL	$146.22 - $169.13 $106,740 - $123,464	-730 Reduced 0.89%	81,703 $12.1 Million
Q2 2020 Jul 10, 2020	SELL	$136.42 - $164.18 $85,808 - $103,269	-629 Reduced 0.76%	82,433 $13.5 Million
Q1 2020 Apr 08, 2020	SELL	$119.05 - $147.35 $352,388 - $436,156	-2,960 Reduced 3.44%	83,062 $11.5 Million
Q4 2019 Jan 10, 2020	BUY	$106.92 - $132.43 $1,496 - $1,854	14 Added 0.02%	86,022 $11.3 Million
Q3 2019 Oct 10, 2019	SELL	$106.79 - $116.16 $95,577 - $103,963	-895 Reduced 1.03%	86,008 $9.62 Million
Q2 2019 Aug 15, 2019	BUY	$110.79 - $129.32 $221,801 - $258,898	2,002 Added 2.36%	86,903 $9.63 Million
Q1 2019 May 14, 2019	SELL	$111.31 - $131.02 $216,275 - $254,571	-1,943 Reduced 2.24%	84,901 $11 Million
Q4 2018 Feb 19, 2019	BUY	$105.9 - $118.64 $487,351 - $545,981	4,602 Added 5.6%	86,844 $10 Million
Q3 2018 Nov 15, 2018	BUY	$85.86 - $107.31 $48,167 - $60,200	561 Added 0.69%	82,242 $8.83 Million
Q2 2018 Aug 15, 2018	BUY	$75.7 - $86.88 $49,205 - $56,472	650 Added 0.8%	81,681 $6.97 Million
Q1 2018 May 21, 2018	SELL	$74.21 - $87.6 $266,117 - $314,133	-3,586 Reduced 4.24%	81,031 $6.27 Million
Q4 2017 Feb 14, 2018	SELL	$81.94 - $87.89 $254,341 - $272,810	-3,104 Reduced 3.54%	84,617 $7.15 Million
Q3 2017 Nov 16, 2017	SELL	$77.07 - $85.54 $45,471 - $50,468	-590 Reduced 0.67%	87,721 $7.5 Million
Q2 2017 Aug 15, 2017	BUY	N/A	88,311	88,311 $7.27 Million

Others Institutions Holding LLY

# of Institutions

4,007

Shares Held

752M

Call Options Held

8.27M

Put Options Held

10.5M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $749B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cypress Capital Group, based on Form 13F filings with the SEC.

News

Stay updated on Cypress Capital Group with notifications on news.

Account

Cypress Capital Group Eli Lilly & CO Transaction History